ProShares UltraShort NASDAQ Biotechnology
7 hedge funds and large institutions have $858K invested in ProShares UltraShort NASDAQ Biotechnology in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
123% more capital invested
Capital invested by funds: $385K → $858K (+$472K)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
17% more funds holding
Funds holding: 6 → 7 (+1)
5.61% more ownership
Funds ownership: 5.79% → 11.4% (+5.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$205K |
| 2 |
Jane Street
New York
|
+$159K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$149K |
| 4 |
PIS
POM Investment Strategies
Raleigh,
North Carolina
|
+$91 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Simplex Trading
Chicago,
Illinois
|
-$1K |
| 2 |
Morgan Stanley
New York
|
-$30 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $465K | +$205K | +6,769 | +78% |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $232K | +$149K | +4,934 | +177% |
|
|
3
Jane Street
New York
| $158K | +$159K | +5,260 | New |
|
4
Citigroup
New York
| $1.28K | – | – | – |
|
|
5
Morgan Stanley
New York
| $1.11K | -$30 | -1 | -3% |
|
|
PIS
6
POM Investment Strategies
Raleigh,
North Carolina
| $75 | +$91 | +3 | New |
|
7
UBS Group
Zurich,
Switzerland
| $15 | – | – | – |
|
|
8
Simplex Trading
Chicago,
Illinois
| – | -$1K | -35 | Closed |
|
BIS Hedge Fund Activity: Q3 2024 in Review
7 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q3 2024, worth a combined $858K — up 123% from $385K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BIS positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $205K. The largest seller was Simplex Trading, exiting entirely with an estimated $1K sold.
- 7 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q3 2024, up from 6 in Q2 2024.
- Funds reported $858K of ProShares UltraShort NASDAQ Biotechnology stock for Q3 2024, up 123% quarter-over-quarter.
- 2 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q3 2024 and 1 closed out, a net change of +1 holder.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q3 2024 was Susquehanna International Group, an estimated $205K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q3 2024 was Simplex Trading, an estimated $1K sold.
Based on aggregated 13F filings for Q3 2024.